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ABSTRACT
Among the many types of leukemia, acute myeloid leukemia (AML) affects 20% of diagnosed
hematological malignancies in pediatric patients (Meshinchi and Arceci, 2007; de Rooij et al.,
2015). Standard chemotherapy regimen remains as the first line treatment for pediatric AML,
however nearly 40% of AML patients may suffer from relapse and eventually die from the
disease (de Rooij et al., 2015). Similarly, it has been reported that 50% of the pediatric AML
relapsed within 12–18 months of diagnosis and 45% of those relapsed were not expected to
survive (Creutzig et al., 2014). Despite advances in cytogenetic analysis through
fluorescence in situ hybridization and multiplex PCR, there is still a need for a better and
comprehensive molecular profiling. For instance, microarray has long been used to study the
gene expression profiles of AML patients. The different profile of gene expression has enabled
clinicians to tailor better treatment for patients and predict whether patients have the tendency
to relapse (Goswami et al., 2009). In a recent study, Handschuch et al. reported that three
genes, ANXA3, S100A9, and WT1 can differentiate between different prognostic types of AML
(Handschuh et al., 2018). The study outcome was in agreement with another study conducted
by Shimada et al. (2012), where a high expression of WT1 gene showed prognostic impact in
pediatric AML (Shimada et al., 2012). Another study by Jo et al. (2015) reported that high
expression of EVI1 and MEL1 could predict the prognosis of pediatric AML (Jo et al., 2015).
However, none of the biomarkers identified from these studies have been translated into
clinical use. Therefore, the search continues for additional promising biomarkers, notably novel
transcripts, novel fusion genes and non-coding RNAs which are not represented in the
microarray platform. Transcriptome sequencing through next generation sequencing
represents an effective approach to discover new genetic information on gene expression
which may contribute to tumorigenesis. Notably, several novel and rare fusion transcripts have
been identified from AML patients via RNA-sequencing (Padella et al., 2015). A recent study
combining whole genome sequencing, whole exome sequencing and RNA sequencing in
pediatric cancers has identified 240 pathogenic variants with increased sensitivity (Rusch et al.,
2018). Previous studies in relapsed AML have shown that the cells acquired additional genetic
mutations that were either different or evolved from subclones of diagnostic blasts cells
(Padella et al., 2015; Rusch et al., 2018). Nevertheless, little is known about the genetic
changes at the transcriptomic level at diagnostic, remission and relapse stages of the same
patients, especially in the Malaysian population.
